JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

Search

China Pharma Holdings Inc

Suletud

1.52 -6.17

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.52

Max

1.62

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

12. nov 2025

China Pharma Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. nov 2025, 21:44 UTC

Tulu

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

3. nov 2025, 23:44 UTC

Market Talk

Nikkei May Rise on Weaker Yen, Hopes for Govt Econ Steps -- Market Talk

3. nov 2025, 23:34 UTC

Market Talk

Gold Edges Lower Amid Lingering Worry Over China's Ending of Tax Incentive -- Market Talk

3. nov 2025, 23:28 UTC

Tulu

Palantir Revenue Hits Another Record as Defense Work Booms -- 2nd Update

3. nov 2025, 23:24 UTC

Tulu

Correct: Grab Holdings Sees FY2025 Adj Ebitda $490M-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3. nov 2025, 23:14 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Global Equities Roundup: Market Talk

3. nov 2025, 23:14 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Deterra's Next CEO Might Bring New Approach to Deals -- Market Talk

3. nov 2025, 23:12 UTC

Tulu

Grab Holdings Sees FY2025 Adj Ebitda $490-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3. nov 2025, 23:09 UTC

Tulu

Grab Holdings 3Q 2Q Adj EBITDA $136.0M Vs. $90.0M>GRAB

3. nov 2025, 23:09 UTC

Tulu

Grab Holdings 3Q Net $17.0M Vs. Net $15.0M >GRAB

3. nov 2025, 23:09 UTC

Tulu

Grab Holdings 3Q Rev $873.0M Vs. $716.0M >GRAB

3. nov 2025, 23:06 UTC

Market Talk
Tulu

Palantir Execs Forecast Future of U.S. Workers In AI World -- Market Talk

3. nov 2025, 22:36 UTC

Market Talk
Tulu

Palantir's U.S. Commercial Business Booms as It Expands AI -- Market Talk

3. nov 2025, 22:31 UTC

Tulu

Franco-Nevada 3Q EPS $1.49 >FNV

3. nov 2025, 22:31 UTC

Tulu

Franco-Nevada 3Q Rev $487.7M >FNV

3. nov 2025, 22:24 UTC

Market Talk

Xero Bulls Expect Improving U.S. Momentum in 1H -- Market Talk

3. nov 2025, 22:19 UTC

Omandamised, ülevõtmised, äriostud

Starbucks Agrees to Sell Stake in China Business -- WSJ

3. nov 2025, 21:59 UTC

Market Talk

RBA Set To Keep Rates On Hold; Remain Data Dependent -- Market Talk

3. nov 2025, 21:54 UTC

Market Talk
Tulu

Westpac's Tech Challenge Keeps Jefferies Cautious -- Market Talk

3. nov 2025, 21:54 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

3. nov 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3. nov 2025, 21:49 UTC

Tulu

Palantir Revenue Hits Another Record as Defense Work Booms -- Update

3. nov 2025, 21:40 UTC

Tulu

Barry Diller's IAC Inks AI Deal With Microsoft. That Isn't Why the Stock Is Sliding. -- Barrons.com

3. nov 2025, 21:31 UTC

Market Talk

Mexican Manufacturing Indexes Pick Up in October -- Market Talk

3. nov 2025, 21:19 UTC

Tulu

Palantir Revenue Hits Another Record as Defense Work Booms -- WSJ

3. nov 2025, 21:11 UTC

Omandamised, ülevõtmised, äriostud

Pfizer Reports Earnings Tuesday. Management Has Big Questions to Answer. -- Barrons.com

3. nov 2025, 21:11 UTC

Tulu

Diamondback Energy: Increasing Full Yr Oil Production Guidance to 495-498 MBO/d and Increasing Annual BOE Guidance to 910-920 MBOE/d >FANG

3. nov 2025, 21:07 UTC

Tulu

Palantir Technologies: Raising 2025 U.S. Comml Rev Guidance to in Excess of $1.433B, Representing a Growth Rate of at Least 104% >PLTR

3. nov 2025, 21:05 UTC

Tulu

Vertex Pharmaceutic Sees 2025 Rev $11.9B-$12B >VRTX

3. nov 2025, 21:05 UTC

Tulu

Palantir Technologies 3Q Net $475.6M >PLTR

Võrdlus sarnastega

Hinnamuutus

China Pharma Holdings Inc Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

0

Osta

0

Hoia

0

Müü

Finantsandmed

$

help-icon Live chat